Gut Microbiota and Coronary Artery Disease: Current Therapeutic Perspectives
Metabolites · 09.02.2023 · 13 (2) · 256
DOI: 10.3390/metabo13020256 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Metabolites, online erschienen am 09.02.2023. Verfasst von Themistoklis Katsimichas und 3 weiteren Autor:innen. Beteiligte Einrichtung: 1st Cardiology Department, National and Kapodistrian University of Athens, Vas. Sofias Avenue 114, 11527 Athens, Greece. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The human gut microbiota is the community of microorganisms living in the human gut. This microbial ecosystem contains bacteria beneficial to their host and plays important roles in human physiology, participating in energy harvest from indigestible fiber, vitamin synthesis, and regulation of the immune system, among others. Accumulating evidence suggests a possible link between compositional and metabolic aberrations of the gut microbiota and coronary artery disease in humans. Manipulating the gut microbiota through targeted interventions is an emerging field of science, aiming at reducing the risk of disease. Among the interventions with the most promising results are probiotics, prebiotics, synbiotics, and trimethylamine N-oxide (TMAO) inhibitors. Contemporary studies of probiotics have shown an improvement of inflammation and endothelial cell function, paired with attenuated extracellular matrix remodeling and TMAO production. Lactobacilli, Bifidobacteria, and Bacteroides are some of the most well studied probiotics in experimental and clinical settings. Prebiotics may also decrease inflammation and lead to reductions in blood pressure, body weight, and hyperlipidemia. Synbiotics have been associated with an improvement in glucose homeostasis and lipid abnormalities. On the contrary, no evidence yet exists on the possible benefits of postbiotic use, while the use of antibiotics is not warranted, due to potentially deleterious effects. TMAO inhibitors such as 3,3-dimethyl-1-butanol, iodomethylcholine, and fluoromethylcholine, despite still being investigated experimentally, appear to possess anti-inflammatory, antioxidant, and anti-fibrotic properties. Finally, fecal transplantation carries conflicting evidence, mandating the need for further research. In the present review we summarize the links between the gut microbiota and coronary artery disease and elaborate on the varied therapeutic measures that are being explored in this context.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- 1st Cardiology Department, National and Kapodistrian University of Athens, Vas. Sofias Avenue 114, 11527 Athens, Greece.
ORCID-Profile: Panagiotis Theofilis
Zitieren
APA
Katsimichas, T., Theofilis, P., Tsioufis, K., & Tousoulis, D. (2023). Gut Microbiota and Coronary Artery Disease: Current Therapeutic Perspectives. Metabolites, 13(2), 256. https://doi.org/10.3390/metabo13020256
Vancouver
Katsimichas T, Theofilis P, Tsioufis K, Tousoulis D. Gut Microbiota and Coronary Artery Disease: Current Therapeutic Perspectives. Metabolites. 2023;13(2):256. doi:10.3390/metabo13020256
BibTeX
@article{Katsimichas2023,
author = {Katsimichas, Themistoklis and Theofilis, Panagiotis and Tsioufis, Konstantinos and Tousoulis, Dimitris},
title = {Gut Microbiota and Coronary Artery Disease: Current Therapeutic Perspectives},
journal = {Metabolites},
year = {2023},
volume = {13},
number = {2},
pages = {256},
doi = {10.3390/metabo13020256}
}
EUVIMED